Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation

NCT02417207 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT02417207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02417207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 4
Overall status
Unknown status
Start date
April 30, 2015
Completion date
April 30, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, liver transplantation